Study Stopped
Loss of investigator staff
Brief Versus Standard Cognitive Behavioral Therapy for Insomnia in Veterans
A Randomized Clinical Trial Comparing Brief and Standard Cognitive-Behavioral Therapies for Insomnia in Veterans
2 other identifiers
interventional
15
1 country
2
Brief Summary
Insomnia is a common condition in Veterans, with prevalence rates as high as 53% among treatment-seeking Veterans. Chronic untreated insomnia is associated with increased risk for functional impairment, psychiatric illness, suicidal ideation, unhealthy lifestyles, and decreased quality of life. Cognitive-Behavioral Therapy for Insomnia (CBT-I) is recognized as the first-line treatment for insomnia. Despite its proven efficacy, CBT-I is not always readily provided and/or accessible to Veterans. To address these limitations, behavioral sleep medicine specialists have endeavored to streamline CBT-I through development of time-shortened variations of CBT-I. Although these modifications show promise for advancing care and access, studies comparing brief treatments to standard CBT-I have yet to be performed. This investigation will therefore compare a 4-session brief CBT-I to VA standard 6-session CBT-I to evaluate whether a brief intervention can provide comparable benefits to sleep, functional, and psychiatric outcomes in Veterans with insomnia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2023
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedStudy Start
First participant enrolled
May 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedMarch 20, 2026
March 1, 2026
2.4 years
February 2, 2023
March 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Insomnia Severity Index (ISI) scores from pretreatment to follow-up
Measure of insomnia severity (0-24; higher score equals worse insomnia)
Week 0 (baseline) and Week 20 (follow-up)
Secondary Outcomes (7)
Change in Functional Outcomes of Sleep Questionnaire 10 (FOSQ-10)
Week 0 (baseline) and Week 20 (follow-up)
Change in Pittsburgh Sleep Quality Index (PSQI) scores from pretreatment to follow-up
Week 0 (baseline) and Week 20 (follow-up)
Change in WHO Disability Assessment Schedule (WHODAS 2.0)
Week 0 (baseline) and Week 20 (follow-up)
Change in Brief Inventory of Psychosocial Functioning (B-IPF)
Week 0 (baseline) and Week 20 (follow-up)
Change in PTSD Checklist for DSM 5 (PCL-5)
Week 0 (baseline) and Week 20 (follow-up)
- +2 more secondary outcomes
Study Arms (2)
Cognitive-Behavioral Therapy for Insomnia (CBT-I)
ACTIVE COMPARATORCompare two behavioral interventions for insomnia
Standard Cognitive-Behavioral Therapy for Insomnia (CBT-I)
ACTIVE COMPARATORStandard VA 6 session version of CBT-I
Interventions
Standard VA 6 session CBT-I
4 session CBT-I
Eligibility Criteria
You may qualify if:
- A diagnosis of insomnia as classified by the (a) Diagnostic and Statistical Manual of Mental Disorders-5 (DSM 5) which includes daytime impairment in functioning for \> 3 months and occurring at least 3 nights per week and (b) subjective sleep disturbance defined by an Insomnia Severity Index (ISI) score \>7 at intake
- Meets current DSM 5 criteria for a comorbid mental health disorder
- No formal therapist guided treatment with brief or standard Cognitive-Behavioral Therapy for Insomnia within the past 2 years
- on stable medication regimen for at least 4 weeks prior to enrollment in study.
You may not qualify if:
- History of a acute or unstable neurological disorder(s), dementia, or premorbid IQ \<70
- Schizophrenia, psychotic disorder, and/or bipolar disorder
- Suicidality more than "medium risk" as determined by the VA Comprehensive Suicide Risk Assessment
- Sleep disturbances other than insomnia (e.g., untreated obstructive sleep apnea, periodic limb movements, narcolepsy, and/or circadian-based sleep disruptions)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
VA San Diego Healthcare System, San Diego, CA
San Diego, California, 92161-0002, United States
VA Finger Lakes Healthcare System, Canandaigua, NY
Canandaigua, New York, 14424-1159, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Colvonen, PhD
VA San Diego Healthcare System, San Diego, CA
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- FED
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 2, 2023
First Posted
February 13, 2023
Study Start
May 1, 2023
Primary Completion
October 1, 2025
Study Completion
October 1, 2025
Last Updated
March 20, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share